Symbols / STRO $25.43 +1.80%
STRO Chart
About
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 416.74M |
| Enterprise Value | 66.57M | Income | -216.77M | Sales | 105.65M |
| Book/sh | -10.26 | Cash/sh | 19.69 | Dividend Yield | — |
| Payout | 0.00% | Employees | 178 | IPO | — |
| P/E | — | Forward P/E | -2.35 | PEG | — |
| P/S | 3.94 | P/B | -2.48 | P/C | — |
| EV/EBITDA | -0.52 | EV/Sales | 0.63 | Quick Ratio | 2.39 |
| Current Ratio | 2.53 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -26.00 | EPS next Y | -10.81 | EPS Growth | — |
| Revenue Growth | 13.80% | Earnings | 2025-11-06 16:00 | ROA | -25.80% |
| ROE | -18.10% | ROIC | — | Gross Margin | 136.66% |
| Oper. Margin | -4.01% | Profit Margin | -205.18% | Shs Outstand | 16.39M |
| Shs Float | 7.78M | Short Float | 3.95% | Short Ratio | 4.70 |
| Short Interest | — | 52W High | 26.54 | 52W Low | 5.20 |
| Beta | 1.48 | Avg Volume | 131.32K | Volume | 179.40K |
| Target Price | $21.25 | Recom | None | Prev Close | $24.98 |
| Price | $25.43 | Change | 1.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.25
Mean price target
2. Current target
$25.43
Latest analyst target
3. DCF / Fair value
$-155.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$25.43
Low
$8.00
High
$51.00
Mean
$21.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-20 | up | Citizens | Market Perform → Market Outperform | $23 |
| 2025-12-22 | main | HC Wainwright & Co. | Neutral → Neutral | $10 |
| 2025-08-12 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-06-16 | up | Piper Sandler | Neutral → Overweight | $2 |
| 2025-05-19 | main | B of A Securities | Underperform → Underperform | $1 |
| 2025-04-29 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-03-17 | down | HC Wainwright & Co. | Buy → Neutral | $2 |
| 2025-03-14 | down | Citizens Capital Markets | Market Outperform → Market Perform | — |
| 2025-03-14 | down | Wedbush | Outperform → Neutral | $2 |
| 2025-03-14 | down | B of A Securities | Buy → Underperform | $1 |
| 2024-12-11 | main | Wells Fargo | Equal-Weight → Equal-Weight | $4 |
| 2024-12-11 | reit | JMP Securities | Market Outperform → Market Outperform | $17 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-10-11 | reit | Piper Sandler | Overweight → Overweight | $11 |
| 2024-10-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-09-16 | reit | JMP Securities | Market Outperform → Market Outperform | $17 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-16 | main | Truist Securities | Buy → Buy | $15 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-15 | main | Oppenheimer | Outperform → Outperform | $10 |
- $STRO stock is down 9% today. Here's what we see in our data. - Quiver Quantitative Mon, 09 Mar 2026 14
- Sutro Biopharma lines up March health-care investor talks in Boston and Miami - Stock Titan Wed, 25 Feb 2026 08
- Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday - MarketBeat hu, 05 Mar 2026 06
- Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance hu, 22 Jan 2026 08
- Gerber of Sutro Biopharma buys $13,606 in STRO stock - Investing.com hu, 16 Oct 2025 07
- Sutro Biopharma Sets 1-for-10 Reverse Stock Split - Nasdaq Mon, 01 Dec 2025 08
- STRO - Sutro Biopharma Latest Stock News & Market Updates - Stock Titan Wed, 12 Nov 2025 08
- Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? - Yahoo Finance Wed, 11 Feb 2026 08
- Pauling, Sutro Biopharma chief admin. ofcr., buys $9993 in STRO stock - Investing.com hu, 16 Oct 2025 07
- Sutro Biopharma (NASDAQ: STRO) enacts 1-for-10 reverse split, cuts shares to 8,519,392 - Stock Titan Mon, 01 Dec 2025 08
- Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
- Sutro Biopharma Stock (STRO) Opinions on Insider Buying Activity - Quiver Quantitative hu, 16 Oct 2025 07
- Biotech Restructuring: Sutro Biopharma Cuts 33% Jobs to Fund Cancer Drug Pipeline Through 2027 - Stock Titan Mon, 29 Sep 2025 07
- $STRO stock is up 9% today. Here's what we see in our data. - Quiver Quantitative hu, 16 Oct 2025 07
- Sutro Biopharma Regains Nasdaq Compliance Following Reverse Stock Split - Quiver Quantitative Wed, 17 Dec 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 788 | — | — | CHUNG JANE | Chief Executive Officer | — | 2026-03-04 00:00:00 | D | nan |
| 1 | 675 | — | — | PAULING DAVID J.D. | General Counsel | — | 2026-03-04 00:00:00 | D | nan |
| 2 | 10938 | — | — | CHUNG JANE | Chief Executive Officer | — | 2026-03-02 00:00:00 | D | nan |
| 3 | 3968 | — | — | GERBER HANS-PETER PH.D. | Officer | — | 2026-03-02 00:00:00 | D | nan |
| 4 | 3698 | — | — | PAULING DAVID J.D. | General Counsel | — | 2026-03-02 00:00:00 | D | nan |
| 5 | 2500 | — | — | CHUNG JANE | Chief Executive Officer | — | 2025-12-12 00:00:00 | D | nan |
| 6 | 50000 | — | Purchase at price 0.80 per share. | MATSUI CONNIE L | Director | — | 2025-10-15 00:00:00 | D | 39950.0 |
| 7 | 19750 | — | Purchase at price 0.81 per share. | CHOW GREGORY KWOK LEE | Chief Financial Officer | — | 2025-10-15 00:00:00 | D | 15998.0 |
| 8 | 12500 | — | Purchase at price 0.80 per share. | CHUNG JANE | Chief Executive Officer | — | 2025-10-15 00:00:00 | D | 10011.0 |
| 9 | 17000 | — | Purchase at price 0.80 per share. | GERBER HANS-PETER PH.D. | Officer | — | 2025-10-15 00:00:00 | D | 13607.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 2.08M | 2.55M | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -186.81M | -67.95M | -119.80M | -93.10M |
| TotalUnusualItems | 9.92M | 12.13M | -4.45M | |
| TotalUnusualItemsExcludingGoodwill | 9.92M | 12.13M | -4.45M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -227.46M | -106.79M | -119.20M | -105.54M |
| ReconciledDepreciation | 7.22M | 6.82M | 5.69M | 4.84M |
| EBITDA | -186.81M | -58.03M | -107.67M | -97.56M |
| EBIT | -194.03M | -64.85M | -113.36M | -102.40M |
| NetInterestIncome | 13.36M | -9.24M | 109.00K | -2.56M |
| InterestExpense | 31.07M | 23.75M | 3.35M | 3.14M |
| InterestIncome | 44.42M | 14.51M | 3.46M | 577.00K |
| NormalizedIncome | -227.46M | -114.63M | -128.79M | -101.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -227.46M | -106.79M | -119.20M | -105.54M |
| TotalExpenses | 300.50M | 243.01M | 196.72M | 160.40M |
| TotalOperatingIncomeAsReported | -238.45M | -89.28M | -128.94M | -98.52M |
| DilutedAverageShares | 7.68M | 6.02M | 5.07M | 4.61M |
| BasicAverageShares | 7.68M | 6.02M | 5.07M | 4.61M |
| DilutedEPS | -29.60 | -17.80 | -23.50 | -22.90 |
| BasicEPS | -29.60 | -17.80 | -23.50 | -22.90 |
| DilutedNIAvailtoComStockholders | -227.46M | -106.79M | -119.20M | -105.54M |
| NetIncomeCommonStockholders | -227.46M | -106.79M | -119.20M | -105.54M |
| NetIncome | -227.46M | -106.79M | -119.20M | -105.54M |
| NetIncomeIncludingNoncontrollingInterests | -227.46M | -106.79M | -119.20M | -105.54M |
| NetIncomeContinuousOperations | -227.46M | -106.79M | -119.20M | -105.54M |
| TaxProvision | 2.36M | 18.19M | 2.50M | 0.00 |
| PretaxIncome | -225.10M | -88.60M | -116.70M | -105.54M |
| OtherIncomeExpense | 9.92M | 12.13M | -4.45M | |
| GainOnSaleOfSecurity | 9.92M | 12.13M | -4.45M | |
| NetNonOperatingInterestIncomeExpense | 13.36M | -9.24M | 109.00K | -2.56M |
| InterestExpenseNonOperating | 31.07M | 23.75M | 3.35M | 3.14M |
| InterestIncomeNonOperating | 44.42M | 14.51M | 3.46M | 577.00K |
| OperatingIncome | -238.45M | -89.28M | -128.94M | -98.52M |
| OperatingExpense | 300.50M | 243.01M | 196.72M | 160.40M |
| ResearchAndDevelopment | 252.04M | 180.43M | 137.17M | 104.40M |
| SellingGeneralAndAdministration | 48.45M | 62.58M | 59.54M | 56.00M |
| GeneralAndAdministrativeExpense | 48.45M | 62.58M | 59.54M | 56.00M |
| OtherGandA | 48.45M | 62.58M | 59.54M | 56.00M |
| TotalRevenue | 62.04M | 153.73M | 67.77M | 61.88M |
| OperatingRevenue | 62.04M | 153.73M | 67.77M | 61.88M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 8.25M | 6.10M | 5.75M | 4.63M |
| ShareIssued | 8.25M | 6.10M | 5.75M | 4.63M |
| TotalDebt | 23.15M | 33.63M | 50.43M | 57.37M |
| TangibleBookValue | 44.60M | 149.65M | 217.05M | 252.56M |
| InvestedCapital | 44.60M | 153.71M | 233.32M | 277.68M |
| WorkingCapital | 211.42M | 327.80M | 286.61M | 176.78M |
| NetTangibleAssets | 44.60M | 149.65M | 217.05M | 252.56M |
| CapitalLeaseObligations | 23.15M | 29.57M | 34.16M | 32.26M |
| CommonStockEquity | 44.60M | 149.65M | 217.05M | 252.56M |
| TotalCapitalization | 44.60M | 149.65M | 220.82M | 268.30M |
| TotalEquityGrossMinorityInterest | 44.60M | 149.65M | 217.05M | 252.56M |
| StockholdersEquity | 44.60M | 149.65M | 217.05M | 252.56M |
| GainsLossesNotAffectingRetainedEarnings | 39.00K | 21.00K | -618.00K | -314.00K |
| OtherEquityAdjustments | 39.00K | 21.00K | -618.00K | -314.00K |
| RetainedEarnings | -786.87M | -559.41M | -452.62M | -333.41M |
| AdditionalPaidInCapital | 831.35M | 708.98M | 670.22M | 586.24M |
| CapitalStock | 83.00K | 61.00K | 58.00K | 46.00K |
| CommonStock | 83.00K | 61.00K | 58.00K | 46.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 342.61M | 321.09M | 189.90M | 88.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 210.71M | 227.34M | 123.35M | 47.11M |
| OtherNonCurrentLiabilities | 1.69M | 1.69M | 119.00K | 146.00K |
| NonCurrentDeferredLiabilities | 193.34M | 202.49M | 89.89M | 0.00 |
| NonCurrentDeferredRevenue | 193.34M | 202.49M | 89.89M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 15.67M | 23.15M | 33.34M | 46.96M |
| LongTermCapitalLeaseObligation | 15.67M | 23.15M | 29.57M | 31.22M |
| LongTermDebt | 3.77M | 15.74M | ||
| CurrentLiabilities | 131.89M | 93.75M | 66.55M | 41.74M |
| OtherCurrentLiabilities | 4.01M | 3.90M | 3.08M | 3.08M |
| CurrentDeferredLiabilities | 69.78M | 20.67M | 16.76M | 5.50M |
| CurrentDeferredRevenue | 69.78M | 20.67M | 16.76M | 5.50M |
| CurrentDebtAndCapitalLeaseObligation | 7.48M | 10.48M | 17.09M | 10.41M |
| CurrentCapitalLeaseObligation | 7.48M | 6.42M | 4.58M | 1.04M |
| CurrentDebt | 4.06M | 12.50M | 9.38M | |
| OtherCurrentBorrowings | 4.06M | 12.50M | 9.38M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.90M | 14.69M | 13.14M | 11.42M |
| PayablesAndAccruedExpenses | 37.72M | 44.02M | 16.48M | 14.41M |
| CurrentAccruedExpenses | 27.22M | 19.41M | 11.68M | 8.40M |
| Payables | 10.49M | 24.61M | 4.80M | 6.01M |
| TotalTaxPayable | 18.00K | 15.16M | 0.00 | |
| AccountsPayable | 10.47M | 9.44M | 4.80M | 6.01M |
| TotalAssets | 387.21M | 470.74M | 406.94M | 341.41M |
| TotalNonCurrentAssets | 43.90M | 49.19M | 53.79M | 122.89M |
| OtherNonCurrentAssets | 8.03M | 4.44M | 2.73M | 2.53M |
| InvestmentsAndAdvances | 0.00 | 68.78M | ||
| InvestmentinFinancialAssets | 0.00 | 68.78M | ||
| AvailableForSaleSecurities | 68.78M | |||
| NetPPE | 35.87M | 44.76M | 51.06M | 51.59M |
| AccumulatedDepreciation | -48.63M | -42.16M | -37.91M | -33.43M |
| GrossPPE | 84.50M | 86.92M | 88.97M | 85.02M |
| Leases | 24.20M | 23.61M | 23.21M | 23.65M |
| ConstructionInProgress | 497.00K | 497.00K | 1.69M | 506.00K |
| OtherProperties | 57.93M | 60.82M | 62.29M | 59.27M |
| MachineryFurnitureEquipment | 1.87M | 1.99M | 1.78M | 1.59M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 343.31M | 421.54M | 353.15M | 218.51M |
| OtherCurrentAssets | 17.80M | 9.85M | 11.67M | 8.12M |
| PrepaidAssets | 8.12M | |||
| Receivables | 8.62M | 36.08M | 7.12M | 12.45M |
| AccountsReceivable | 8.62M | 36.08M | 7.12M | 12.45M |
| CashCashEquivalentsAndShortTermInvestments | 316.89M | 375.62M | 334.36M | 197.94M |
| OtherShortTermInvestments | 126.59M | 306.35M | 287.11M | 167.52M |
| CashAndCashEquivalents | 190.30M | 69.27M | 47.25M | 30.41M |
| CashEquivalents | 29.45M | |||
| CashFinancial | 963.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -194.64M | -115.93M | -4.31M | -97.00M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -7.00K | |
| RepaymentOfDebt | -4.08M | -12.50M | -9.38M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 96.53M | 11.97M | 56.27M | 0.00 |
| CapitalExpenditure | -3.10M | -4.32M | -7.86M | -15.32M |
| InterestPaidSupplementalData | 310.00K | 1.13M | 1.87M | 2.05M |
| IncomeTaxPaidSupplementalData | 17.52M | 379.00K | 0.00 | 103.00K |
| EndCashPosition | 191.16M | 70.14M | 48.13M | 31.29M |
| BeginningCashPosition | 70.14M | 48.13M | 31.29M | 207.02M |
| ChangesInCash | 121.02M | 22.01M | 16.84M | -175.74M |
| FinancingCashFlow | 94.05M | 137.55M | 48.31M | 3.26M |
| CashFlowFromContinuingFinancingActivities | 94.05M | 137.55M | 48.31M | 3.26M |
| NetOtherFinancingCharges | -509.00K | 135.72M | -463.00K | -987.00K |
| ProceedsFromStockOptionExercised | 2.12M | 2.37M | 1.88M | 4.25M |
| NetCommonStockIssuance | 96.53M | 11.97M | 56.27M | -7.00K |
| CommonStockPayments | 0.00 | 0.00 | -7.00K | |
| CommonStockIssuance | 96.53M | 11.97M | 56.27M | 0.00 |
| NetIssuancePaymentsOfDebt | -4.08M | -12.50M | -9.38M | 0.00 |
| NetLongTermDebtIssuance | -4.08M | -12.50M | -9.38M | 0.00 |
| LongTermDebtPayments | -4.08M | -12.50M | -9.38M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 218.51M | -3.92M | -35.02M | -97.31M |
| CashFlowFromContinuingInvestingActivities | 218.51M | -3.92M | -35.02M | -97.31M |
| NetOtherInvestingChanges | 9.00K | 9.00K | ||
| NetInvestmentPurchaseAndSale | 221.61M | 391.00K | -27.17M | -82.00M |
| SaleOfInvestment | 683.13M | 460.69M | 189.50M | 166.73M |
| PurchaseOfInvestment | -461.52M | -460.30M | -216.67M | -248.73M |
| NetPPEPurchaseAndSale | -3.10M | -4.32M | -7.86M | -15.32M |
| PurchaseOfPPE | -3.10M | -4.32M | -7.86M | -15.32M |
| OperatingCashFlow | -191.54M | -111.62M | 3.55M | -81.68M |
| CashFlowFromContinuingOperatingActivities | -191.54M | -111.62M | 3.55M | -81.68M |
| ChangeInWorkingCapital | 8.90M | -34.38M | 104.41M | -17.62M |
| ChangeInOtherWorkingCapital | 6.06M | -31.05M | 95.37M | -12.61M |
| ChangeInOtherCurrentLiabilities | -6.42M | -4.58M | 1.90M | -2.73M |
| ChangeInPayablesAndAccruedExpense | -6.65M | 30.11M | 5.34M | 8.57M |
| ChangeInAccruedExpense | -7.35M | 25.30M | 6.56M | 5.87M |
| ChangeInPayable | 706.00K | 4.81M | -1.23M | 2.71M |
| ChangeInAccountPayable | 706.00K | 4.81M | -1.23M | 2.71M |
| ChangeInPrepaidAssets | -11.56M | 109.00K | -3.54M | -3.96M |
| ChangeInReceivables | 27.46M | -28.96M | 5.34M | -6.89M |
| ChangesInAccountReceivables | 27.46M | -28.96M | 5.34M | -6.89M |
| OtherNonCashItems | 36.97M | 16.82M | 2.92M | 6.16M |
| StockBasedCompensation | 24.69M | 24.91M | 26.30M | 23.24M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -9.92M | -12.13M | 4.45M |
| AmortizationOfSecurities | -9.72M | -9.07M | -364.00K | 2.78M |
| DepreciationAmortizationDepletion | 7.22M | 6.82M | 5.69M | 4.84M |
| DepreciationAndAmortization | 7.22M | 6.82M | 5.69M | 4.84M |
| OperatingGainsLosses | -32.14M | -4.07M | ||
| GainLossOnInvestmentSecurities | -32.14M | -4.07M | ||
| NetIncomeFromContinuingOperations | -227.46M | -106.79M | -119.20M | -105.54M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for STRO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|